EUPRAXIA PHARMACEUTICALS INC.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
The yearly report of certain Canadian companies, filed under a joint US and Canadian system. It is the main yearly account these companies give US investors, largely as filed in Canada.
FY2024 · Filed Mar 20, 2025
Use the contents to explore the available documents and sections.
EPRX$6.89+4.4%Stored close · as of Nov 6, 2026
Contents
EX-99.2 · CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS
| December 31,2024 | December 31,2023 | |
|---|---|---|
| ASSETS | ||
| Current assets | ||
| Cash | $33,101,294 | $19,341,756 |
| Prepaid expenses and deposits | 1,106,512 | 270,710 |
| Amounts receivable (Note 4) | 228,872 | 190,612 |
| Total current assets | 34,436,678 | 19,803,078 |
| Non-current assets | ||
| Prepaid expenses | 80,761 | 6,904 |
| Property and equipment, net (Note 5) | 357,893 | 409,587 |
| Right-of-use asset, net (Note 6) | 67,023 | 46,660 |
| Total assets | $34,942,355 | $20,266,229 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT) | ||
| Current liabilities | ||
| Accounts payable and accrued liabilities (Note 7) | $3,031,527 | $3,921,875 |
| Loans payable – current portion (Note 8) | — | 62,709 |
| Lease liability – current portion (Note 9) | 71,859 | 53,316 |
| Payable to Auritec (Note 10) | — | 5,000,000 |
| Convertible debt (Note 11) | — | 10,336,003 |
| Total liabilities | 3,103,386 | 19,373,903 |
| Shareholders’ equity | ||
| Preferred shares, without par value; unlimited shares authorized; issued and outstanding: 8,905,638 (December 31, 2023: nil (Notes 12(c)) | 31,705,219 | — |
| Common shares, without par value; unlimited shares authorized; issued and outstanding: 35,641,603 (December 31, 2023 - 27,282,165 (Note 12(b)) | 116,360,066 | 92,913,585 |
| Additional paid-in capital (Notes 12(b), 12(d) and 12(e))Deficit | 20,503,904 (131,003,831) | 17,510,469 (105,501,295) |
| Accumulated other comprehensive loss | (4,160,555) | (2,706,552) |
| Equity attributable to the owners of the Company | 33,404,803 | 2,216,207 |
| Non-controlling interest | (1,565,834) | (1,323,881) |
| Total shareholders’ equity | 31,838,969 | 892,326 |
| Total liabilities and shareholders’ equity | 34,942,355 | $20,266,229 |
Nature of business and going concern (Note 1)
Commitments and Contingencies (Note 1
)
Subsequent event (Note 22)
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.